For RFS, high expression of OLFML2B, MT1M, and SIDT2 indicated a poor RFS of patients with GC, whereas gastric cancer patients with higher expression of CYP4X1 possessed better RFS from TCGA cohort (Figure 4). Here, SIDT2 is linked to gastric cancer.